Mathematical modelling of cancer cell invasion of tissue: The role of the urokinase plasminogen activation system

Mathematical Models and Methods in Applied Sciences

Volumn 15, Issue 11, 2005, Pages 1685-1734

  Chaplain, M A J ^a   Lolas, G ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Chemotaxis; Haptotaxis; Reaction diffusion; Spatio temporal heterogeneity; Tumour invasion of tissue

Indexed keywords

EID: 27644463491     PISSN: 02182025     EISSN: None     Source Type: Journal    
DOI: 10.1142/S0218202505000947     Document Type: Article

References (129)

1. J. A. Adam and N. Bellomo, A Survey of Models for Tumour-Immune System Dynamics (Birkhäuser, 1996).
2. J. A. Aguirre Ghiso, D. F. Alonso, E. F. Farías, D. E. Gomez and E. Bal De Kier Joffè, Deregulation of the signaling pathways controlling urokinase production. Its relationship with the invasive phenotype, Euro. J. Biochem. 263 (1999) 295-304.
3. J. A. Aguirre Ghiso, K. Kovalsji and L. Ossowski, Tumor dormancy induced by down-regulation of urokinase receptor in human carcinoma involves integrin and MAPK signaling, J. Cell Biol. 147 (1999) 89-103.
4. J. A. Aguirre Ghiso, D. Liu, A. Mignatti, K. Kovalski and L. Ossowski, Urokinase receptor and fibronectin regulate the EKR MARK to p38 MARK activity ratios that determine carcinoma cell proliferation or dormancy in vivo, Molecular Biology of the Cell 12 (2001) 863-879.
5. B. Alberts, D. Bray, J. Lewis, M. Raff, K. Roberts and J. D. Watson, Molecular Biology of the Cell (Garland Publishing, 1994).
6. A. R. A. Anderson, A hybrid mathematical model of solid tumour invasion: The importance of cell adhesion, Math. Med. Biol. (in press) (2005).
7. A. R. A. Anderson, M. A. J. Chaplain, E. L. Newman, R. J. C. Steele and A. M. Thompson, Mathematical modelling of tumour invasion and metastasis, J. Theor. Med. 2 (2000) 129-154.
8. A. R. A. Anderson and M. A. J. Chaplain, Continuous and discrete mathematical models of tumor-induced angiogenesis, Bull. Math. Biol. 60 (1998) 857-899.
9. P. A. Andreasen, L. Sottrup-Jensen, L. Kjøller, A. Nykjor, S. K. Moestrup, C. M. Petersen and J. Gliemann, Receptor-mediated endocytosis of plasminogen activators and activator/inhibitor complexes, FEBS Fed. Euro. Biochem. Soc. 338 (1994) 239-245.
10. P. A. Andreasen, L. Kjøller, L. Christensen and M. J. Duffy, The urokinase-type plasminogen activator system in cancer metastasis: A review, Int. J. Cancer 72 (1997) 1-22.
11. P. A. Andreasen, R. Egelund and H. H. Petersen, The plasminogen activation system in tumor growth, invasion, and metastasis, Cellular and Molecular Life Sci. 57 (2000) 25-40.
12. R. P. Araujo and D. L. S. McElwain, A history of the study of solid tumour growth: The contribution of mathematical modelling, Bull. Math. Biol. 66 (2004) 1039-1091.
13. S. Aznavoorian, M. L. Stracke, H. Krutzsch, E. Schiffmann and L. A. Liotta, Signal transduction for chemotaxis and haptotaxis by matrix molecules in tumor cells, J. Cell Biol. 110 (1990) 1427-1438.
14. 3 mediates chemotactic and haptotactic motility in human melanoma cells through different signaling pathways, J. Biol. Chem. 271 (1996) 3247-3254.
15. S. Aznavoorian, A. N. Murphy, W. G. Stetler-Stevenson and L. A. Liotta, Molecular aspects of tumor cell invasion and metastasis, Cancer 71 (1993) 1368-1383.
16. L. M. Bafetti, T. N. Young, Y. Itoh and S. M. Stack, Intact vitronectin induces matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression and enhanced cellular invasion by melanoma cells, J. Biol. Chem. 273 (1998) 143-149.
17. N. Bellomo, A. Bellouquid and E. De Angelis, The modelling of the immune competition by generalized kinetic (Boltzmann) models: Review and research perspectives, Math. Compu. Model. 37 (2003) 1131-1142.
18. D. Besser, P. Verde, Y. Nagamine and F. Blasi, Signal transduction and the u-PA/u-PAR system, Fibrinolysis, 10 (1996) 215-237.
19. R. Bicknell, C. E. Lewis and N. Ferrara, Tumour Angiogenesis (Oxford Univ. Press, 1997).
20. F. Blasi, J-D. Vassalli and K. Danø, Urokinase-type plasminogen activator: Proenzyme, receptor, and inhibitors, J. Cell Biol. 104 (1987) 801-804.
21. F. Blasi, Proteolysis, cell adhesion, chemotaxis, and invasiveness are regulated by the u-PA-uPAR-PAl-1 system, Thrombosis and Haemostasis 82 (1999) 298-304.
22. C. Borgfeldt, Ovarian Tumours Prevalence, malignancy risk and significance of the Plasminogen activation system, PhD Thesis, University of Lund, Lund (2001).
23. D. Bray, Cell Movements from Molecules to Motility (Garland Publishing, 2000).
24. N. Busso, S. K. Masur, D. Lazega, S. Waxman and L. Ossowski, Induction of cell migration by prourokinase binding to its receptor: possible mechanism for signal-transduction in human epithelial cells, J. Cell Biol. 126 (1994) 259-270.
25. H. M. Byrne, M. A. J. Chaplain, G. J. Pettet and D. L. S. McElwain, A mathematical model of trophoblast invasion, J. Theor. Med. 1 (1998) 275-286.
26. H. M. Byrne, M. A. J. Chaplain, G. J. Pettet and D. L. S. McElwain, An analysis of a mathematical model of trophoblast invasion, Appl. Math. Lett. 14 (2001) 1005-1010.
27. S. M. Carlin, M. Roth and J. L. Black, Urokinase potentiates PDGF-induced chemotaxis of human airway smooth muscle cells, Amer. J. Physiol. 284 (2003) 1020-1026.
28. P. Carmeliet and R. K. Jain, Angiogenesis in cancer and other diseases, Nature 407 (2000) 249-256.
29. S. B. Carter, Haptotaxis and the mechanism of cell motility, Nature 213 (1967) 256-260.
30. A. F. Chambers and L. M. Matrisian, Changing views of the role of matrix metallo-proteinases in metastasis, J. Nat. Cancer Inst. 89 (1997) 1260-1270.
31. A. F. Chambers, A. C. Groom and I. C. MacDonald, Dissemination and growth of cancer cells in metastatic sites, Nature Rev. 2 (2002) 563-572.
32. M. A. J. Chaplain, The mathematical modelling of tumour angiogenesis and invasion, Acta Biotheor. 43 (1995) 387-402.
33. H. A. Chapman, Plasminogen activators, integrins, and the coordinated regulation of cell adhesion and migration, Current Opinion in Cell Biol. 9 (1997) 714-724.
34. M. H. Chun, Plasmin induces the formation of multicellular spheroids of breast cancer cells, Cancer Lett. 117 (1997) 51-56.
35. D. Collen, C. Zamarron, H. R. Lijnen and M. Hoylaerts, Activation of plasminogen by prourokinase, J. Biol. Chem. 261 (1986) 1259-1266.
36. W. D. Comper, Extracellular Matrix Volume 2 Molecular Components and Interactions (Harwood Academic, 1996).
37. M. Conese and F. Blasi, The urokinase/urokinase-receptor system and cancer-invasion, Baillière's Clin. Haematology 8 (1995) 365-389.
38. M. Conese and F. Blasi, Urokinase/urokinase receptor system: Internalization/degradation of urokinase-serpin complexes. Mechanism and regulation, Biol. Chem. Hoppe-Seyler 376 (1995) 143-155.
39. A. S. G. Curtis, The measurement of cell adhesiveness by an absolute method, J. Embryol. Exp. Morphol. 22 (1969) 305-325.
40. R.-P. Czekay, K. Aertgeerts, S. A. Curriden and D. J. Loskutoff, Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins, J. Cell Biol 160 (2003) 781-791.
41. K. Danø, P. A. Anderson, J. Grondahl-Hansen, P. Kristensen, L. S. Nielsen and L. Skriver, Plasminogen activators, tissue degradation and cancer, Adv. Cancer Res. 44 (1985) 139-266.
42. K. Danø, N. Behrendt, N. Brunner, V. Ellis, M. Ploug and C. Pyke, The urokinase receptor. Protein structure and role in plasminogen activation and cancer invasion, Fibrinolysis 8 (Suppl. 1) (1994) 189-203.
43. 3 integrin induce chemotaxis and cytoskeleton reorganization through different signaling pathways, Oncogens. 20 (2001) 2032-2043.
44. G. Deng, S. A. Curriden, S. Wang, S. Rosenberg and D. J. Loskutoff, Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release?, J. Cell Biol. 134 (1996) 1563-1571.
45. M. J. Duffy, Urokinase plasminogen activator: A prognostic marker in multiple types of cancer, J. Surg. Oncol. 71 (1999) 130-135.
46. M. J. Duffy, Clinical uses of tumor markers: A critical review, Critical Rev. Clinical Lab. Sci. 38 (2001) 225-262.
47. L. Edelstein-Keshet, Mathematical Models in Biology (McGraw-Hill, 1988).
48. V. Ellis and K. Danø, Plasminogen activation by receptor-bound urokinase a kinetic study with both cell-associated and isolated receptor, J. Biol. Chem. 266 (1991) 12752-12758.
49. V. Ellis, Functional analysis of the cellular receptor for urokinase in plasminogen activation, J. Biol. Chem. 271 (1996) 14799-14784.
50. V. Ellis, S. A. Whawell, F. Werner and J. J. Deadman, Assembly of urokinase receptor-mediated plasminogen activation complexes involves direct, non-active-site interactions between urokinase and plasminogen, Biochem. 38 (1999) 651-659.
51. F. Fazioli, M. Resnati, N. Sidenius, Y. Higashimoto, E. Appella and F. Blasi, A urokinase-sensitive region of the human urokinase receptor is responsible for its chemotactic activity, The EMBO J. 16 (1997) 7279-7286.
52. I. J. Fidler, The biology of cancer metastasis or, "you cannot fix it if you do not know how it works", Bioessays 13 (1991) 551-554.
53. I. J. Fidler, The pathogenesis of cancer metastasis: the "seed and soil" hypothesis revisited, Nature Rev. 3 (2002) 1-6.
54. J. Folkman, Tumour angiogenesis, Adv. Cancer Res. 19 (1974) 331-358.
55. J. Folkman, The vascularization of tumours, Sci. Amer. 234 (1976) 58-73.
56. J. Folkman and M. Klagsbrun, Angiogenic factors, Science 235 (1987) 442-447.
57. S. B. Fox, M. Taylor, J. Grøndahl-Hansen, S. Kakolyris, K. C. Gatter and A. L. Harris, Plasminogen activator inhibitor-1 as a measure of vascular re-modelling in breast cancer, J. Pathology 195 (2001) 236-243.
58. R. A. Gatenby, Models of tumour-host interaction as competing populations: Implications for tumor biology and treatment, J. Theor. Biol. 176 (1995) 447-455.
59. R. A. Gatenby and E. T. Gawlinski, A reaction-diffusion model of cancer invasion, Cancer Res. 56 (1996) 5745-5753.
60. M. R. Gyetko, R. F. Todd III, C. C. Wilkinson and R. G. Sitrin, The urokinase receptor is required for human monocyte chemotaxis in vitro, J. Clinical Investigation 93 (1994) 1380-1387.
61. M. R. Gyetko, G.-H. Chen, R. A. McDonald, R. Goodman, G. B. Huffnagle, C. C. Wilkinson, J. A. Fuller and G. B. Toews, Urokinase is required for the pulmonary inflammatory response to Cryptococcus neoformans, J. Clinical Investigation 97 (1996) 1818-1826.
62. G. Hamilton, Multicellular spheroids as an in vitro model, Cancer Lett. 131 (1998) 29-34.
63. D. Hanahan and R. A. Weinberg, The hallmarks of cancer, Cell 100 (2000) 57-70.
64. J. P. Irigoyen, P. Muñoz-Cánoves, L. Montero, M. Koziczak and Y. Nagamine, The plasminogen activator system: Biology and regulation, Cellular and Molecular Life Sci. 56 (1999) 104-132.
65. T. L. Jackson, S. R. Lubkin, S. R. Siemens, N. O. Kerr, P. D. Senter and J. D. Murray, Mathematical and experimental analysis of localization of anti-tumour anti-body-enzyme conjugates, British J. Cancer 80 (1999) 1747-1753.
66. J. Jankun, H. W. Merrick and P. J. Goldblatt, Expression and localization of elements of the plasminogen activation system in benign breast disease and breast cancers, J. Cellular Biochem. 53 (1993) 135-144.
67. S. M. Kanse, C. Kost, O. G. Wilhelm, P. A. Andreasen and K. T. Preissner, The urokinase receptor is a major vitronectin-binding protein on endothelial cells, Exp. Cell Res. 224 (1996) 344-353.
68. S. Karlin, 11th R. A. Fisher Memorial Lecture - Kin Selection and Altruism, Proc. Roy. Soc. London 219 (1983) 327-353.
69. R. J. B. King, Cancer Biology (Prentice Hall, 2000).
70. L. Kjøller, S. M. Kanse, T. Kirkegaard, K. W. Rodenburg, E. Rønne, S. L. Goodmann, K. T. Preissner, L. Ossowski and P. A. Andreasen, Plasminogen activator inhibitor-1 represses integrin-and vitronectin-mediated cell migration independently of its function as an inhibitor of plasminogen activation, Exp. Cell Res. 232 (1997) 420-429.
71. L. Kjøller, The urokinase plasminogen activator receptor in the regulation of the actin cytoskeleton and cell motility, Biol. Chem. 383 (2002) 5-19.
72. E. C. Kohn and L. A. Liotta, Molecular insights into cancer invasion: Strategies for prevention and intervention, Cancer Res. 51 (1995) 1856-1862.
73. L. Lachowicz, Micro and meso scales of description corresponding to a model of tissue invasion by solid tumours, Math. Mod. Meth. Appl. Sci. to appear, (2005).
74. Eds. J. M. Lackie and P. C. Wilkinson, Biology of the Chemotactic Response (Cambridge Univ. Press, 1981).
75. D. A. Lauffenburger and A. F. Horwitz, Cell migration: A physically integrated molecular process, Cell 84 (1996) 359-369.
76. L. A. Liotta, Tumour invasion and metastases: role of the extracellular matrix, Cancer Res. 46 (1986) 1-7.
77. L. A. Liotta and W. G. Stetler-Stevenson, Tumor invasion and metastasis as targets for cancer therapy, Cancer Res. 51 (1991) 5054-5059.
78. L. A. Liotta, and T. Clair, Checkpoint for invasion, Nature 405 (2000) 287-288.
79. G. Lolas, Mathematical modelling of the urokinase plasminogen activation system and its role in cancer invasion of tissue, PhD Thesis, University of Dundee (2003).
80. N. V. Mantzaris, S. Webb and H. G. Othmer, Mathematical modelling of tumour-induced angiogenesis 49 (2004) 111-187.
81. A. Matzavinos, M. A. J. Chaplain and V. A. Kuznetsov, Mathematical modelling of the spatio-temporal response of cytotoxic T-lymphocytes to a solid tumour, Math. Med. Biol. IMA 21 (2004) 1-34.
82. A. Matzavinos and M. A. J. Chaplain, Travelling-wave analysis of a model of the immune response to cancer, C.R. Biol. 327 (2004) 995-1008.
83. J. B. McCarthy, S. L. Palm and L. T. Furcht, Migration by haptotaxis of a Schwann cell tumor line to the basement membrane glycoprotein laminin, J. Cell Biol. 97 (1983) 772-777.
84. J. B. McCarthy, S. T. Hagen and L. T. Furcht. Human fibronectin contains distinct adhesion- and motility-promoting domains for metastatic melanoma cells, J. Cell Biol. 102 (1986) 179-188.
85. P. Mignatti and D. B. Rifkin, Biology and biochemistry of proteinases in tumor invasion, Physio. Rev. 73 (1993) 161-195.
86. S. Mohanam, C. L. Gladson, C. N. Rao and J. S. Rao, Biological significance of the expression of urokinase-type plasminogen activator receptors (uPARs) in brain tumors, Frontiers in Biosci. 4 (1999) 178-187.
87. J. D. Murray, Mathematical Biology: Spatial Models and Biomedical Applications (Springer-Verlag, 2003).
88. J. D. Murray, The optimal scheduling of two drugs with simple resistance for a problem in cancer chemotherapy, IMA J. Math. Appl. Med. Biol. 4 (1997) 283-303.
89. M. C. Naski, D. A. Lawrence, D. F. Mosher, T. J. Podor and D. Ginsburg, Kinetics of inactivation of α-thrombin by plasminogen activator inhibitor-1, J. Biol. Chem. 268 (1993) 12367-12372.
90. D. H. D. Nguyen, I. M. Hussaini and S. L. Gonias, Binding of urokinase-type plasminogen activator to its receptor in MCF-7 cells activates extracellular signal-regulated kinase 1 and 2 which is required for increased cellular motility, J. Biol. Chem. 273 (1998) 8502-8507.
91. A. Nykjær, M. Conese, E. I. Christensen, D. Olson, O. Cremona, J. Gliemann and F. Blasi, Recycling of the urokinase receptor upon internalization of the uPA: Serpin complexes, The EMBO J. 16 (1997) 2610-2620.
92. A. Nykjær, B. Møller, R. F. Todd, T. Christensen, P. A. Andreasen, J. Gliemann and C. M. Petersen, The Urokinase receptor: An activation antigen in human lympocytes, J. Immunol. 152 (1994) 505-516.
93. A. Okubo, Diffusion and Ecological Problems: Mathematical Models (Springer-Verlag, 1980).
94. M. E. Orme and M. A. J. Chaplain, A mathematical model of vascular tumour growth and invasion, Math. Comput. Model. 23 (1996) 43-60.
95. M. E. Orme and M. A. J. Chaplain, Two-dimensional models of tumour angiogenesis and anti-angiogenesis strategies, IMA J. Math. Appl. Med. Biol. 14 (1997) 189-205.
96. L. Ossowski and J. A. Aguirre-Ghiso, Urokinase receptor and integrin partnership: Coordination of signaling for cell adhesion, migration and growth, Current Opinion in Cell Biol. 124 (2000) 613-620.
97. S. L. Parsons, S. A. Watson, P. D. Brown, H. M. Collins and R. J. C. Steele, Matrix metalloproteinases, Brit. J. Surg. 84 (1997) 160-166.
98. M. S. Pepper, A.-P. Sappino, R. Stöcklin, R. Montesano, L. Orci and J.-D. Vassalli, Upregulation of urokinase receptor expression on migrating endothelial cells, J. Cell Bio;. 122 (1993) 673-684.
99. M. S. Pepper, Role of the matrix metalloproteinase and plasminogen aetivator-plasmin systems in angiogenesis, Arteriosclerosis, Thrombosis and Vascular Biol. 21 (2001) 1104-1117.
100. M. S. Pepper, Extracellular proteolysis and angiogenesis, Thrombolysis and Haemostasis, 86 (2001) 346-355.
101. A. J. Perumpanani, J. A. Sherratt, J. Norbury and H. M. Byrne, Biological inferences from a mathematical model for malignant invasion, Invasion & Metastasis 16 (1996) 209-221.
102. A. J. Perumpanani, D. L. Simmons, A. J. H. Gearing, K. M. Miller, G. Ward, J. Norbury, M. Schneemann and J. A. Sherratt, Extracellular matrix-mediated chemotaxis can impede cell migration, Proc. Roy. Soc. London, Ser. B 265 (1998) 2347-2352.
103. A. J. Perumpanani and H. M. Byrne, Extracellular matrix concentration exerts selection pressure on invasive cells, Euro. J. Cancer 35 (1999) 1274-1280.
104. O. Plekhanova, Y. Parfyonova, R. Bibilashvily, S. Domogatskii, V. Stepanova, D. C. Gulba, A. Agrotis, A. Bobik and V. Tkachuk, Urokinase plasminogen activator augments cell proliferation and neiontima formation in injured arteries via proteolytic mechanisms, Atherosclerosis 159 (2001) 297-306.
105. T. Plesner, N. Behrendt and M. Ploug, Structure, function and expression on blood and bone marrow cells of the urokinase-type plasminogen activator receptor, uPAR, STEM Cells 15 (1997) 398-408.
106. T. J. Podor, S. G. Shaughnessy, M. N. Blackburn and C. B. Peterson, New insights into the size and stoichiometry of the plasminogen activator inhibitor type-1/vitronectin complex, J. Biol. Chem. 275 (2000) 25402-25410.
107. Ed. L. Preziosi, Cancer Modelling and Simulation (Chapman &: Hall/CR.C Press, 2003).
108. J. M. Rakic, C. Maillard, M. Jost, K. Bajou, V. Masson, L. Devy, V. Lambert, J. M. Foidart and A. Noël, Role of plasminogen activator-plasmin system in tumor angiogenesis, Cellular and Molecular Life Sci. 60 (2003) 463-473.
109. 2-antiplasmin, Thrombosis Res. 105 (2002) 247-256.
110. M. Resnati, M. Guttinger, S. Valcamonica, N. Sidenius, F. Blasi and F. Fazioli, Proteolytic cleavage of the urokinase receptor substitutes for the agonist-induced chemotactic effect, EMBO J. 9 (1996) 467-470.
111. K. C. Robbins, L. Summaria, D. Elwyn and G. H. Barlow, Further studies on the purification and characterization of human plasminogen and plasmin, J. Biol. Chem. 240 (1965) 541-550.
112. J. A. Sherratt and J. D. Murray, Models of epidermal wound healing, Proc. of the Roy. Soc. of London, Ser. B 241 (1990) 29-36.
113. J. A. Sherratt and M. A. Nowak, Oncogenes, anti-oncogenes and the immune response to cancer: A mathematical model, Proc. of the. Roy. Soc. London, Ser. B 248 (1992) 261-271.
114. C. L. Stokes, D. A. Lauffenburger and S. K. Williams, Migration of individual microvessel endothelial cells: stochastic model and parameter measurement, J. Cell Sci. 99 (1991) 419-430.
115. C. L. Stokes and D. Lauffenburger, Analysis of the roles of microvessel endothelial cell random motility and chemotaxis in angiogenesis, J. Theor. Biol. 152 (1991) 377-403.
116. E. L. Stott, N. F. Britton, J. A. Glazier and M. Zajac, Stochastic simulation of benign avascular tumour growth using the Potts model, Math. Comput. Model. 30 (1999) 183-198.
117. S. Suzuki, Y. Hayashi, Y. Wang, T. Nakamura, Y. Morita, K. Kawasaki, K. Ohta, N. Aoyama, S. R. Kim, H. Itoh, Y. Kuroda and W. F. Doe, Urokinase type plasminogen activator receptor expression in colorectal neoplasms, Gut 43 (1998) 798-805.
118. Z. Szymańska, Analysis of immunotherapy models in the context of cancer dynamics, Appl. Math. Comput. Sci. 13 (2003) 407-418.
119. K. R. Swanson, E. C. Alvord and J. D. Murray, A quantitative model for differential motility of gliomas in grey and white matter, Cell Proliferation 33 (2000) 317-329.
120. R. Swiercz, J. D. Wolfe, A. Zaher and J. Jankun, Expression of the plasminogen activation system in kidney cancer correlates with its aggressive phenotype, Clin. Cancer Res. 4 (1998) 869-877.
121. T. Tarui, A. P. Mazar, D. B. Cines and Y. Takada, Urokinase-type plasminogen activator receptor (CD87) is a ligand for integrins and mediates cell-cell interaction, J. Biol. Chem. 276 (2001) 3983-3990.
122. S. Turner and J. A. Sherratt, intercellular adhesion and cancer invasion: A discrete simulation using the extended Potts model, J. Theor. Biol. 216 (2002) 85-100.
123. D. A. Waltz and H. A. Chapman, Reversible cellular adhesion to vitronectin linked to urokinase receptor occupancy, J. Biol. Chem. 269 (1994) 14746-14750.
124. D. A. Waltz, L. R. Natkin, R. M. Fujita, Y. Wei and H. A. Chapman, Plasmin and plasminogen activator inhibitor type 1 promote cellular motility by regulating the interaction between the urokinase receptor and vitronectin, J. Clin. Investigation 100 (1997) 58-67.
125. Y. Wei, D. A. Waltz, N. Rao, R. J. Drummond, S. Rosenberg and H. A. Chapman, Identification of the urokinase receptor as an adhesion receptor for vitronectin, J. Biol. Chem. 269 (1994) 32380-32388.
126. Y. Wei, X. Yang, Q. Liu, J. A. Wilkins and H. A. Chapman, A role for caveolin and the urokinase receptor in integrin-mediated adhesion and signaling, J. Cell Biol. 144 (1999) 1285-1294.
127. D. R. Welch and C. W. Rinker-Schaeffer, What defines a useful marker of metastasis in human cancer?, J. Nat. Cancer Inst. 91 (1999) 1351-1353.
128. M. Yebra, L. Goretzki, M. Pfeifer and B. M. Mueller, Urokinase-type plasminogen activator binding to its receptor stimulates tumor cell migration by enhancing integrin-mediated signal transduction, Exp. Cell Res. 250 (1999) 231-240.
129. W. Yu, J. Kim and L. Ossowski, Reduction in surface urokinase receptor forces malignant cells into a protracted state of dormancy, J. Cell Biol. 137 (1997) 767-777.